Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
|Grade||Last Price||% Change||Price Change|
BHVN closed up 2.28 percent on Monday, March 19, 2018, on 1.22 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical BHVN trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 19||New Downtrend||Bearish||0.00%|
|Mar 19||Hammer Candlestick||Bullish||0.00%|
|Mar 19||Wide Bands||Range Expansion||0.00%|
|Mar 19||Lower Bollinger Band Touch||Weakness||0.00%|
|Mar 19||Oversold Stochastic||Weakness||0.00%|
|Mar 16||200 DMA Resistance||Bearish||2.28%|
|Mar 16||Volume Surge||Other||2.28%|
|Mar 16||Wide Bands||Range Expansion||2.28%|
|Mar 16||Down 3 Days in a Row||Weakness||2.28%|
|Mar 16||Down 4 Days in a Row||Weakness||2.28%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BHVN news...
|52 Week High||39.51|
|52 Week Low||17.0|
|200-Day Moving Average||28.8573|
|50-Day Moving Average||30.668|
|20-Day Moving Average||30.7575|
|10-Day Moving Average||29.102|
|Average True Range||2.0729|
|Chandelier Exit (Long, 3 ATRs )||28.4013|
|Chandelier Exit (Short, 3 ATRs )||31.3987|
|Upper Bollinger Band||35.3166|
|Lower Bollinger Band||26.1984|
|Percent B (%b)||0.18|
|MACD Signal Line||-0.2733|
|Market Cap||998 Million|
|Num Shares||35.8 Million|
|Price-to-Earnings (P/E) Ratio||-3.69|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||32.30|
|Resistance 3 (R3)||31.90||30.03||31.55|
|Resistance 2 (R2)||30.03||28.89||30.22||31.30|
|Resistance 1 (R1)||28.93||28.19||29.48||29.33||31.06|
|Support 1 (S1)||25.96||25.92||26.51||26.36||24.62|
|Support 2 (S2)||24.09||25.22||24.28||24.38|
|Support 3 (S3)||22.99||24.09||24.13|
|Support 4 (S4)||23.39|